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ABSTRACT
Uncompromised by chronic disease-related comorbidities, human umbilical cord blood (UCB) progenitor cells with high aldehyde dehydrogenase activity (ALDHhi cells) stimulate blood vessel regeneration after intra-muscular transplantation. However, implementation of cellular therapies using
UCB ALDHhi cells for critical limb ischemia, the most severe form of severe peripheral artery disease,
is limited by the rarity (<0.5%) of these cells. Our goal was to generate a clinically-translatable, allogeneic cell population for vessel regenerative therapies, via ex vivo expansion of UCB ALDHhi cells
without loss of pro-angiogenic potency. Puriﬁed UCB ALDHhi cells were expanded >18-fold over 6days under serum-free conditions. Consistent with the concept that ALDH-activity is decreased as
progenitor cells differentiate, only 15.1% 6 1.3% of progeny maintained high ALDH-activity after culture. However, compared to fresh UCB cells, expansion increased the total number of ALDHhi cells
(2.7-fold), CD341/CD1331 cells (2.8-fold), and hematopoietic colony forming cells (7.7-fold).
Remarkably, injection of expanded progeny accelerated recovery of perfusion and improved limb
usage in immunodeﬁcient mice with femoral artery ligation-induced limb ischemia. At 7 or 28 days
post-transplantation, mice transplanted with expanded ALDHhi cells showed augmented endothelial
cell proliferation and increased capillary density compared to controls. Expanded cells maintained
pro-angiogenic mRNA expression and secreted angiogenesis-associated growth factors, chemokines,
and matrix modifying proteins. Coculture with expanded cells augmented human microvascular
endothelial cell survival and tubule formation under serum-starved, growth factor-reduced conditions. Expanded UCB-derived ALDHhi cells represent an alternative to autologous bone marrow as
an accessible source of pro-angiogenic hematopoietic progenitor cells for the reﬁnement of vascular
regeneration-inductive therapies. STEM CELLS TRANSLATIONAL MEDICINE 2017;6:1607–1619

SIGNIFICANCE STATEMENT
The development of cell therapies to improve limb perfusion in patients with critical limb ischemia
has been an area of intense preclinical investigation. In previous studies, we established that
human high aldehyde dehydrogenase activity (ALDHhi) cells stimulate revascularization in mice with
surgically induced limb ischemia. However, the low number of ALDHhi cells in umbilical cord blood
(UCB) limits widespread application in humans. Here, we demonstrate that UCB ALDHhi cells are
readily expanded (18-fold) under defined, serum-free conditions without diminishing vascular
regenerative functions. Transplantation of day 6 expanded cells into mice with acute hindlimb ischemia accelerated the recovery of perfusion, increased limb use, and augmented capillary density
within 7 days post-transplantation. Importantly, pro-longed expansion out to 9 days resulted in
complete loss of regenerative function after transplantation in vitro. Thus, we propose that initial
purification for high ALDH-activity followed by 6-days expansion to increase the pro-angiogenic progenitor pool poses a promising allogeneic approach for the treatment of ischemic diseases.

INTRODUCTION
Cardiovascular disease remains a leading cause of
death in North America, and the economic burden
associated with cardiovascular diseases now
exceeds $300 billion in the U.S. alone [1, 2]. Since
Asahara et al. ﬁrst described a role for circulating

bone marrow (BM)-derived cells in blood vessel
regeneration [3], the development of cellular
therapies to treat chronic ischemic diseases such
as coronary [4–6] or peripheral arterial disease
(PAD) [7, 8], has been the focus of intense investigation. Based upon considerable pre-clinical
promise [9–11], clinical trials transplanting
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formation during coculture in vitro. Thus, expansion of allogeneic
UCB ALDHhi cells represents a clinically-applicable strategy for the
development of new regenerative therapies to prevent limb loss
in patients with severe PAD.

MATERIALS AND METHODS
Purification of UCB ALDHhi Cells
Human UCB was collected by venipuncture after obtaining
informed consent prior to scheduled C-sections at the London
Health Sciences Birthing Centre. The Human Studies Research
Ethics Board at Western University approved all studies. UCB was
ﬁrst depleted of cells expressing lineage-speciﬁc markers using
RosetteSep human progenitor enrichment cocktail, and Lin– cells
were assessed for ALDH-activity using the Aldeﬂuor assay (StemCell Technologies, Vancouver, BC, https://www.stemcell.com)
described previously [1–6]. High-speed cell sorting for cells with
high ALDH-activity was performed on a FACS Aria III ﬂow cytometer (BD Biosciences, Mississauga, ON, https://www.bdbiosciences.
com).

Expansion of UCB ALDHhi Cells
Puriﬁed UCB ALDHhi cells (104 cells per cm2) were expanded in
ﬁbronectin-coated plates in serum-free, xeno-free X-vivo 15 media
(Lonza, Basel, Switzerland, www.lonza.com/) supplemented with
10 ng/ml stem cell factor (SCF), Fms-related tyrosine kinase 3
ligand (Flt3L), and thrombopoietin (TPO, Life Technologies, Burlington, ON, https://www.thermoﬁsher.com). Media was changed
every 3 days to minimize culture-induced hematopoietic cell differentiation [38].

Assessment of ALDH-Activity and Cell Surface Marker
Expression
After 3-, 6-, or 9-days expansion, cell progeny was harvested and
reassessed for ALDH-activity using ALDH-inhibition to re-establish
regions for ALDHlo versus ALDHhi cells [28]. Subsequently, cells
were colabeled with anti-human antibodies for CD34 and CD133
(progenitor), CD3 (T-lymphocytes), CD14 (monocytes), CD11b
(macrophages), CD19 (B-Lymphocytes), CD33 (myeloid cells). All
antibodies were from BD Biosciences except CD133 (Miltenyi Biotech, Auburn, CA, www.miltenyibiotec.com). Viable (7AAD-excluding) cells were analyzed simultaneously for ALDH-activity and cell
surface marker expression using a six-color protocol on an LSRII
ﬂow cytometer (BD Biosciences) at the London Regional Flow
Cytometry Facility. Data was analyzed using FlowJo software
(Treestar, Ashland, OR, https://www.ﬂowjo.com).

Hematopoietic Colony Formation In Vitro
Fresh UCB ALDHhi cells or expanded progeny were seeded at limiting dilution (200–1,000 cells) in semisolid Methocult H4434
(StemCell Technologies). Colony formation was scored at day 14
based on morphology for erythrocytes (BFU-E), granulocytes
(CFU-G), macrophages (CFU-M), granulocytes/macrophages (CFUGM), or mixed colonies (CFU-Mixed) containing all three lineages.

Femoral Artery Ligation Surgery, Transplantation, and
Quantification of Limb Perfusion/Use
To induce unilateral hind limb ischemic injury in vivo, surgical ligation and resection of the right femoral artery and vein proximal to
the saphenous and popliteal arteries, with cauterization of the
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autologous BM cells in humans have proven disappointing
[12–14], with variable and modest improvements in cardiovascular
[13–16] or PAD [16, 17] outcomes. Recent preclinical studies have
refocused on functional characterization of puriﬁed, more homogeneous cell populations and the use of human cell xenotransplantation models to better understand inductive vascular
regenerative mechanisms [18–23]. Multiple groups have shown
that pro-angiogenic hematopoietic cells can support vessel repair
via paracrine signals [19, 20, 22–27]. We have demonstrated that
transplantation of human BM or umbilical cord blood (UCB) progenitor cells with high aldehyde dehydrogenase (ALDH) activity, a
self-protective enzyme highly expressed in multiple progenitor lineages, can accelerate recovery from ischemic injury [22]. Importantly, transplanted ALDHhi cells recovered perfusion more
effectively than unpuriﬁed mononuclear cells (MNC) or monocyteselected cells [22, 28]. Although ALDHhi cell retention in ischemic
muscle was transient, collateral small vessel formation was stimulated by paracrine signals from injected ALDHhi cells [22, 28].
Based on these promising ﬁndings, a phase I/II, double-blind,
randomized controlled trial was performed comparing autologous
BM ALDHhi cells to MNC after intramuscular injection into patients
with severe CLI at high risk for limb amputation [29]. Autologous
ALDHhi cells were safely administered to all patients, and compared to baseline, patients administered ALDHhi cells showed
improvements in Rutherford category and ankle-bracheal index at
6 and 12 weeks. However, both groups showed improved quality
of life scores, no changes in ischemic ulcer grade or transcutaneous PO2 were observed, and one patient from each group
required limb amputation [29]. The authors concluded the initial
data showed promise and further study was warranted to determine whether ALDHhi cell therapy has a meaningful effect on
wound healing or amputation-free survival. Due to accumulating
evidence that progenitor cell content and regenerative function of
autologous BM is signiﬁcantly reduced in patients with chronic
ischemic disease-related comorbidities [30–33], continuation of
this trial has focused on intermittent claudication (PACE trial) [34],
a less severe manifestation of PAD.
Early in ontogeny, and untouched by chronic disease-related
pathologies such as high lipid and glucose toxicity, allogeneic UCB
cells have emerged an alternative to the use of autologous BM
cells. Although government initiatives in North America and
Europe to phenotype and bank UCB samples has increased the
availability of UCB cells for cell therapies, implementation of trials
using UCB ALDHhi cells is hindered by the rarity of the population,
as ALDHhi cells account for only 0.4% of total MNC in UCB [28].
However, the need to increase the number of UCB-derived progenitor cells for efﬁcient reconstitution of transplanted patients
with leukemia and other hematological disorders has led to the
development of translatable culture strategies for cell expansion
using xeno-free conditions with minimal growth factor supplementation [35–39].
Here we characterize the preservation of pro-angiogenic
potency by UCB-derived ALDHhi cells after expansion using
clinically-applicable conditions, and present a 6-day strategy to
increase cell numbers for vascular regenerative therapies. After a
18-fold increase in the number of myeloid cells available for transplantation, intramuscular transplantation of day 6 expanded bulk
progeny accelerated recovery of perfusion and limb use within 7
days, and increased collateral capillary density as effectively as
fresh ALDHhi cells. Expanded cells actively secreted vascular regenerative growth factors, chemokines and matrix modifying proteins
that correlated with improved endothelial cell survival and tube
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Assessment of Revascularization
Frozen adductor muscle sections were ﬁxed in 10% formalin
(Sigma), blocked with mouse-on-mouse reagent (Vector Labs, Burlingame, CA, https://www.vectorlabs.com), and capillary density
in both limbs was quantiﬁed at 7 or 28 days post-transplantation
using rat anti-mouse CD31 (BD Biosciences) and peroxidaselabeled anti-rat secondary (Vector Labs) antibodies visualized with
DAB substrate. CD311 cells were counted in a blinded fashion
from nine ﬁelds per section. Immunoﬂuorescence microscopy was
used to visualize proliferating (EdU1) CD311 cells as previously
described [40].

Microarray Analyses
mRNA from 5 3 105 fresh UCB ALDHhi cells (N 5 3) or day 6
expanded cells (N 5 3) was extracted using mRNeasy Mini kits
(Qiagen, Mississauga, ON, https://www.qiagen.com). Nanodrop
readings ensured equivalent mRNA concentration between samples. Microarray was performed using human Affymetrix 1.0ST
chips (Affymetrix, Santa Carla, CA, www.affymetrix.com) at the
London Regional Genomics Centre. mRNAs > 1.5-fold differentially expressed (FDR < .01) between expanded versus fresh
ALDHhi cells were identiﬁed using Partek Genomics Suite (Partek,
St Louis, MO, www.partek.com). Gene Ontology terms for mRNAs
encoding proteins with extracellular localization were analyzed for
known angiogenic functions.

Pro-Angiogenic Protein Secretion
4 3 104 HMVEC or expanded cells were cultured alone, or 2 3
104 HMVEC and 2 3 104 day 6 expanded cells were cultured in
direct contact for 72 hours to generate Endothelial Basal Media
(EBM2, serum and growth factor-free) conditioned by both cell
types. Conditioned media was assessed for angiogenesisassociated cytokines, chemokines, and proteases using human
C1000 angiogenesis enzyme-linked immunosorbent assay (ELISA)
arrays (RayBiotech, Norcross, GA, www.raybiotech.com). Chemiluminescent intensities generated by HMVEC alone were normalized to 1 as described in the manufacturer’s protocol and relative

www.StemCellsTM.com

changes in signal intensity generated by coculture were calculated
using cells from three expanded UCB samples (N 5 3).

HMVEC Survival and Tubule Formation During Coculture
40 3 103 expanded cells were seeded into porous (1 lm) hanging
transwells suspended above 40 3 103 HMVEC. Serving as controls, 40 3 103 HMVEC were cultured alone in EBM2 (Lonza) without growth factors or serum, or Endothelial Growth Media
(EGM2, Lonza) with growth factors (EGF, FGF, IGF-1, VEGF) and 5%
FBS. After 72 hours, trypan-blue excluding HMVEC were enumerated by blinded hemocytometer counts. Cells were used to assess
apoptosis frequency by 7AAD / AlexaFluor-488 annexin V staining
by ﬂow cytometry. To assess tubule formation, 1.4 3 104 HMVEC
were seeded on growth factor-reduced Matrigel (GelTrex, Life
Technologies), and cultured with or without 1.4 3 104 day 6expanded cells. The integrity of tubule networks formed at 6, 24,
and 48 hours was enumerated by blinded counts of complete
branch points under light microscopy.

Statistics
Analysis of signiﬁcance was performed by one-way ANOVA
with Tukey’s multiple comparison tests for phenotype assessment, CFU assays, cytokine arrays, and vessel density histology.
Two-way repeated measures analysis of variance (ANOVA) with
Bonferroni post hoc test was used for LDPI and Matrigel data
with time course analyses. Limb usage data was analyzed using
unpaired Student’s t test. All statistical analyses were performed using Graphpad Prism software.

RESULTS
UCB ALDHhi Cells Decreased ALDH Expression During
Culture
We have previously shown that fresh UCB ALDHhi cells stimulate
vascular regeneration after i.m.-transplantation [28]. However, a
typical UCB sample yields 4 3 105 ALDHhi cells, limiting therapeutic applications. We set out to expand ALDHhi cells with minimal differentiation using clinically-applicable culture conditions
[36–38]. Gates were established for low ALDH-activity (R2) using
ALDH-inhibition with diethylamniobenzaldehyde (Aldeﬂuor 1
DEAB, Fig. 1A), and cells with high ALDH-activity elicited >5-fold
shift in ﬂuorescence intensity allowing for selection of ALDHlo (R2,
16.2% 6 3.6%) and ALDHhi (R3, 2.4% 6 0.4%) cells by FACS
(N 5 15). After culture with minimal growth factor supplementation (10 ng/ml SCF, Flt3L, TPO), ALDHlo cells showed poor survival
and limited proliferation. In contrast, ALDHhi cells expanded efﬁciently. Puriﬁed ALDHhi cells expanded 2.5 6 0.4-fold over the ﬁrst
3 days, and generated signiﬁcantly increased cell numbers at
day 6 (18.1 6 1.7-fold, **, p < .01), and day 9 (38.9 6 6.0-fold,
**, p < .01). However, the frequency of progeny retaining high
ALDH-activity diminished with culture time from 30.5% 6 2.5% at
day 3, to 15.1% 6 1.3% at day 6, to 6.0% 6 1.0% at day 9 (Fig.
1B,1C). Thus, short-term culture increased cell numbers but was
accompanied by progressively reduced ALDHhi cell frequency, an
indication of cell differentiation during culture.

Total ALDHhi Cell Number was Maximized at 6 Days
Culture Duration
Next, we determined total ALDHhi cell content in 3-day increments during culture. During the initial (Day 0–3) stage of
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superﬁcial epigastric artery branches was performed on anesthetized NOD/SCID (Jackson Laboratory, Bar Harbour, ME, https://
www.jax.org) or NOD/SCID/MPSVII mice as previously described in
detail [2, 3, 6]. Within 24 hours, mice were transplanted by i.m.injection (10 ll) at three sites into the adductor muscle of the
ischemic limb and between ligation landmarks with a total of 2 3
105 fresh ALDHhi cells or 5 3 105 expanded progeny. Cell doses
were selected based on the previously published dose of fresh
ALDHhi cells required to recover perfusion and the expected loss of
ALDHhi cell frequency during culture [28]. Anesthetized mice were
warmed at 378C for 5 minutes before perfusion in hind limbs was
assessed using laser Doppler perfusion imaging (LDPI, Moor Instruments, Devon, U.K., https://www.us.moor.co.uk) as previously
described [2, 3, 6]. LDPI was performed after surgery and the perfusion ratio (PR) in the surgical versus control limb was quantiﬁed
to ensure equivalent induction of severe limb ischemia (PR < 0.1)
in each mouse. LDPI was also performed at 3, 7,14, 21, and 28
days after transplantation to track the recovery of perfusion over
time. CatWalk equipment and software (CatWalk 7.1, Noldus,
Wageningen, Netherlands, http://www.noldus.com/) was used to
quantify limb usage 24 hours after surgery and at 7 or 28 days
post-transplantation. Use of the injured limb was quantiﬁed by the
ratio of print intensity in the surgical versus contralateral limb.
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Figure 1. Puriﬁcation and expansion of human UCB ALDHhi cells. Representative ﬂow cytometry plots showing the puriﬁcation of ALDHhi
cells from human UCB. (A): Lin– cells treated with DEAB established selection criteria for ALDHlo (R2) and ALDHhi gates (R3). ALDHhi cells represented a rare subset (2.4% 6 0.4%) of Lin– cells. (B): Representative ﬂow cytometry plots showing expanded progeny with low versus high
ALDH-activity after culture for 3, 6, or 9 days. (C): The frequency of cells retaining high ALDH-activity diminished as culture time progressed.
(D): Fold increase in total cells, ALDHhi cells, and ALDHlo cells was calculated at days 3, 6, or 9 compared to the number of cells seeded at day
0. Cell progeny at day 6 demonstrated signiﬁcant expansion (2.7 6 0.4-fold) of total ALDHhi cells. Data represent mean 6 SEM from 15 UCB
samples. Statistical analyses were performed by ANOVA with Tukey’s multiple comparisons test relative to cells seeded at day 0 (*, p < .05;
**, p < .01; ***, p < .001). Abbreviations: DEAB, diethylaminobenzaldehyde; ALDH, aldehyde dehydrogenase; ALDHhi, high aldehyde dehydrogenase activity; ALDHlo, low aldehyde dehydrogenase activity; Lin–, Lineage depleted; UCB, umbilical cord blood.

culture, modest cell expansion (2.5-fold) was accompanied by
>3-fold loss in ALDHhi cell frequency from >99.0% purity at
seeding to 30.5% 6 2.5% at day 3 (Fig. 1C) [36]. In contrast,
expansion was robust (7-fold) between days 3–6 with 2-fold
loss of ALDHhi cell frequency (Fig. 1C). Finally, total cell expansion was 2-fold between days 6–9, and ALDHhi cell frequency

dropped 2.5-fold from 15.1 6 1.33 at day 6 to 6.0% 6 1.0% at
day 9. Although total cell number increased between days 6–9,
ALDHhi cell number was unchanged during the last 3 days culture (p 5 .48), Thus, ALDHhi cell content was maximal
(2.7 6 0.4-fold, **, p < .01) at day 6 (Fig. 1D), and 6 days was
identiﬁed as the optimal duration for ALDHhi cell expansion.
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Expanded Cells Showed Diminished Expression of
Progenitor Cell Surface Markers
Expanded cells were also assessed for progenitor cell surface
marker expression. Expression of CD34 and/or CD133 are commonly used to identify primitive cells with hematopoietic repopulating function [35, 36]. Concurrent with diminished ALDHhi cell
frequency during culture, expanded progeny also showed a progressive decline in the frequency of CD341 cells. Compared to
parental UCB ALDHhi cells that highly coexpressed CD34 at

www.StemCellsTM.com

92.5% 6 2.7%, CD34 expression on total expanded cells dropped
to 48.2 6 9.8% at day 3 (**, p < .01), 15.5% 6 4.4% at day 6
(***, p < .01), 4.5% 6 0.4% at day 9 (***, p < .01) (Supporting
Information Table 1). Reduction in CD1331 or CD341/CD1331 cell
frequencies followed a similar pattern (Fig. 2A, 2B). We next
assessed whether cells that retained high ALDH-activity better
maintained primitive cell surface marker expression (Fig. 2A).
Indeed, the loss of CD34/CD133 coexpression was signiﬁcantly
delayed in the ALDHhi subset (Fig. 2B). Cell progeny also retained
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Figure 2. Expanded cells with high ALDH-activity coexpressed primitive surface markers. (A): Representative ﬂow cytometry plots showing
CD34 and CD133 coexpression on expanded cells at 3, 6, or 9 days culture. (B): The frequency of cells that coexpressed CD34/CD133 was signiﬁcantly increased in the ALDHhi cell subset. (C): Expansion kinetics for total CD341 cells, CD1331 cells, or CD341/CD1331 cells during culture. CD341, CD1331, and CD341/CD1331 cell content was signiﬁcantly increased in total cells at days 6 and 9 compared to Day 0 controls.
At day 6, CD341/CD1331 cells were almost exclusively contained within the ALDHhi cell subset. However, within the ALDHhi subset there was
no increase in total CD341, CD1331, or CD341/CD1331 cells after day 6. Data represent mean 6 SEM from ﬁve umbilical cord blood samples. Statistical analyses were performed by ANOVA with Tukey’s multiple comparison test (*, p < .05; **, p < .01). Abbreviations: ALDHhi,
high aldehyde dehydrogenase activity; ALDHlo, low aldehyde dehydrogenase activity.
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high expression of the pan-leukocyte marker CD45 (>98%), and
the myeloid marker Siglec-3 (CD33, >95%) throughout culture,
and acquisition of lineage-speciﬁc markers for monocytes (CD14),
or macrophages (CD11b) was not observed (Supporting Information Table 1). Collectively, expansion of UCB ALDHhi cells resulted
in progressive loss of primitive phenotype without commitment
to monocyte or macrophage lineages.

Total ALDHhi/CD341/CD1331 Cell Content was
Maximized at 6 Days Culture Duration
Total CD34, CD133, and CD34/CD133 cell content was calculated
at each time point. CD341, CD1331 and CD341/CD1331 cell content was signiﬁcantly increased within total cells at day 6 and 9
(Fig. 2C). In contrast, CD34/CD133 coexpression within ALDHhi
cells actually decreased between day 6 and 9, suggesting ALDHactivity was reduced prior to the loss of primitive cell surface
marker expression. Thus, primitive ALDHhi/CD341/CD1331 cell

number was maximal at day 6 and loss of high ALDH-activity was
identiﬁed as an early indicator of cell differentiation.

Total Hematopoietic Colony Formation was Increased
After Expansion
Cultured cells harvested at day 6 or day 9 were plated at limiting
dilution in methylcellulose to assess hematopoietic CFU production compared to parental ALDHhi cells. Although multipotent colony formation was maintained throughout culture (Fig. 3A), the
frequency of colonies formed at day 6 (1 CFU in 7.3 cells) and day
9 (1 CFU in 9.4 cells) was reduced compared to fresh ALDHhi cells
(1 CFU in 3.1 cells, Fig. 3B). Expanded cells showed decreased frequency of macrophage (CFU-M) and granulocyte (CFU-G) colonies,
while CFU-GM and CFU-Mixed colonies were unchanged. Taking
into account 18-fold expansion at day 6 or 39-fold at day 9, total
CFU content was increased 7.7 6 0.7-fold at 6 days and
12.8 6 2.0-fold at 9 days (Fig. 3C). Thus, UCB ALDHhi cell expansion
increased total HPC available for clinical application.
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Figure 3. Total hematopoietic progenitor cell number was increased after expansion. Fresh umbilical cord blood ALDHhi cells or expanded cells
harvested at day 6 or day 9 were plated at limiting dilution in methylcellulose media to compare hematopoietic CFU production. (A): The frequency of CFU-G and CFU-M colonies was decreased at 6 or 9 days culture. (B): This resulted in signiﬁcantly reduced total colony formation from
1 CFU in 3.1 ALDHhi cells fresh cells (Day 0), to 1 CFU in 7.3 expanded cells at day 6, or 1 CFU in 9.4 expanded cells at day 9. (C): Taking into
account total cell number was increased 18.1 6 1.7-fold at day 6, and 38.9 6 6.0-fold at day 9, total CFU content compared to fresh ALDHhi cells
was increased 7.7 6 0.7-fold after 6 days culture and 12.8 6 2.0-fold after 9 days culture. Data represent mean 6 SEM from 5 UCB samples. Statistical analyses were performed by ANOVA with Tukey’s multiple comparison test (*, p < .05; **, p < .01). Abbreviations: ALDHhi, high aldehyde
dehydrogenase; BFU, E, blast forming unit- erythrocyte; CFU-G, colony forming unit- granulocyte; CFU-M, colony forming unit- macrophage; CFUGM, colony forming unit- granulocyte and macrophage; CFU-mixed, colony forming unit containing erythrocytes, granulocytes, and macorphages.
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Transplantation of Day 6 Expanded Cells Improved Limb
Perfusion and Usage

Transplanted Mice Showed Increased Capillary Density
and Endothelial Cell Proliferation
Adductor muscle cryosections from surgical and contralateral
limbs were stained for CD31 to enumerate capillary densities (Fig.
5A, 5B). Mice injected with PBS or day 9 expanded cells showed a
signiﬁcant loss of murine CD311 cells in the ischemic limb at 7 or
28 days post-transplantation (Fig. 5C, 5D). In contrast, mice transplanted with day 6 expanded cells showed increased capillary density at 7 (Fig. 5C) and 28 days (Fig. 5D) post-transplantation.
Despite limited survival of transplanted cells beyond 7 days in the
ischemic limb [28], transplantation of day 6 expanded cells stimulated endogenous murine CD311 capillary formation in the ischemic hind limb within 7 days post-injection.
Mice also received i.p.-injection of EdU 24 hours prior to euthanasia to label proliferating cells at 7 days post-transplantation.

www.StemCellsTM.com

Day 6 Expanded Cells Retain a Pro-Angiogenic
Transcription Profile
To further investigate potential vascular regenerative mechanisms
induced by the paracrine activity of transplanted cells, we performed Affymetrix microarray comparing global mRNA expression
in day 6 expanded cells compared to parental ALDHhi cells. We
have previously shown fresh ALDHhi cells possess a pro-angiogenic
transcription pattern [28]. As predicted from phenotype data
observed by ﬂow cytometry showing a progressive reduction of
ALDH-activity and progenitor cell surface marker expression during
culture (Supporting Information Table 1), expanded cells expressed
signiﬁcantly less ALDH1A1 (p 5 2.24 3 1025), KIT (CD117, p 5 8.31
3 1026) and PROM1 (CD133, p 5 6.88 3 1024) mRNA compared
to fresh ALDHhi cells. Expanded cells also showed increased transcription of angiogenic cytokines including epidermal growth factor
(EGF), vascular endothelial growth factor A and B (VEGF-A, VEGF-B),
angiopoietin-1 (ANGPT1), insulin-like growth factor binding protein
3 (IGFBP3), and matrix modifying proteins including tissue inhibitor
of metalloproteinases 1 and 3 (TIMP-1, TIMP-3, Supporting Information Table 2), indicating the retention and possible enhancement of
a vascular regenerative transcription proﬁle after 6 days culture.

Expanded Cells Secreted Pro-Angiogenic Cytokines,
Chemokines, and Matrix Proteins
Next, HMVEC or day 6 expanded cells were grown alone or in contact cocultures in EBM2 without serum or growth factor supplementation. After 48 hours, conditioned media was collected and
assessed for secreted proteins using human angiogenesis ELISA
arrays (Supporting Information Fig. 1). Both HMVEC and expanded
cells secreted growth factors, chemokines, and matrix proteases
associated with angiogenenic processes. Notably, coculture of
both cell types increased detection of several pro-angiogenic cytokines (angiopoietin-2 and EGF), chemokines (CXCL1,2,3, IL8, CCL5),
and proteases (MMP-9, TIMP-1, TIMP-2).

Coculture with Expanded Cells Improved HMVEC Tube
Formation and Survival In Vitro
To assess the impact of coculture on endothelial cell functions,
HMVEC were plated in growth factor reduced Matrigel with or
without day 6 expanded cells. After 6 and 24 hours, HMVEC cocultured with expanded cells formed more tubule branch points
compared to HMVEC grown alone in EBM2 (Fig. 7A), and coculture supported tube formation equal to HMVEC bathed in EGM2.
Expanded cells plated alone did not form tubes (data not shown).
Thus, contact with day 6 expanded cells promoted HMVEC tubule
formation under growth factor-restricted conditions.
HMVEC were also grown in EBM2 media with or without day
6 expanded cells in noncontact transwells. After 72 hours under
fully supplemented conditions (EGM2), HMVEC demonstrated a
4-fold increase in total cell number, whereas culture in growth
factor-free EBM2 resulted in 2-fold reduced cell number. Transwell
coculture with day 6 expanded cells promoted HMVEC survival in
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We have previously demonstrated that parental UCB ALDHhi cells
accelerate recovery of perfusion after transplantation into mice
with hindlimb ischemia [28]. To assess whether expanded ALDHhi
cells retained vascular regenerative function in vivo, parental UCB
ALDHhi cells (2 3 105) or expanded cells (5 3 105) collected after
6 or 9 days culture were microinjected into the ischemic muscle
of NOD/SCID mice with unilateral hindlimb ischemia induced by
femoral artery ligation. Cell doses were adjusted to account for
increased cell availability and reduced ALDHhi cell frequency after
culture. Importantly, 5 3 105 expanded progeny contained
75,000 ALDHhi cells at day 6, or 25,000 ALDHhi cells at day 9,
well below the injected dose (2 3 105) of fresh ALDHhi cells. Mice
injected with PBS established the baseline recovery of perfusion
from 0.09 6 0.01 at Day 0 to 0.44 6 0.01 at Day 28 (Fig. 4A, 4E).
Mice injected with fresh ALDHhi cells showed accelerated recovery
of perfusion by day 7 (Fig. 4B, 4E) with a plateau at day 14
(PR 5 0.65 6 0.03). Despite >2-fold decrease in total ALDHhi cells
injected after culture, mice injected with expanded cells harvested
at day 6 showed accelerated recovery of perfusion similar to fresh
ALDHhi cells (Fig. 4C, 4E). By 7 days post-transplantation, limb perfusion was signiﬁcantly improved (PR 5 0.45 6 0.09) compared to
PBS-control (PR 5 0.27 6 0.03) and increased perfusion persisted
to day 28 (PR 5 0.79 6 0.06). In contrast, mice injected with cells
harvested at day 9 showed PRs that mirrored PBS-controls (Fig.
4D, 4E). Collectively, UCB ALDHhi cells could be expanded up to 6
days and retain the capacity to improve perfusion after transplantation [40]. Extending culture to 9 days resulted in loss of vascular
regenerative function.
The Noldus Catwalk system was used to assess the recovery
of ischemic limb use by measuring paw print intensity of the
ischemic versus contralateral hind limb. Recordings used to generate paw print intensity ratios for representative mice are shown
online (Supporting Information Video 1). At 24h post-surgery,
mice demonstrated reduced paw print intensity in the ischemic
limb compared to pre-surgery controls (Fig. 4F). Although mice
transplanted with day 9 expanded cells showed no improvement
in limb usage, mice injected with day 6 expanded cells showed
increased paw print intensity (Fig. 4F) at 7 days posttransplantation. At day 28, paw print intensity ratio for each group
were equivalent to pre-surgery controls (data not shown). Thus,
accelerated limb use correlated with recovery of perfusion in mice
transplanted with day 6 expanded cells.

CD311/EdU1 cells (arrows) were clearly detected in the ischemic
muscle of mice transplanted with day 6 expanded cells (Fig. 6A,
6B). Compared to mice injected with PBS or day 9 expanded cells,
mice transplanted with day 6 expanded cells showed increased
endothelial cell proliferation speciﬁcally in the ischemic muscle (Fig.
6C). These data suggest increased capillary density occurred in part
via the early induction of mouse CD311 cell proliferation sustained
for at least 7 days.
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Figure 4. Transplantation of day 6 expanded cells accelerated the recovery of perfusion and improved usage of the ischemic limb. (A–D):
Representative LDPI following femoral artery ligation and i.m.-injection of PBS (n 5 10), 2 3 105 fresh umbilical cord blood (UCB) ALDHhi cells
(n 5 9), or 5 3 105 expanded cells harvested at day 6 (n 5 7) or day 9 (n 5 8). (E): Transplantation of fresh ALDHhi cells or day 6 expanded
cells accelerated the recovery perfusion compared to PBS-injected controls. However, transplantation of day 9 expanded cells showed perfusion ratios equivalent to PBS-injected controls. (F): Noldus catwalk paw print intensity at 7 days post-transplantation showed mice transplanted with day 6 expanded cells (n 5 6) regained use of their ischemic leg faster than PBS-injected controls (n 5 6). Data represent
mean 6 SEM from 6 UCB samples. Statistical analyses were performed by 2-way ANOVA with Bonferroni’s multiple comparisons test (*,
p < .05; ***, p < .001). Abbreviation: PBS, phosphate buffered saline.

EBM-2 (Fig. 7B). HMVEC were also harvested at 24 hours and
assessed for apoptosis using 7AAD with annexin V-staining by ﬂow
cytometry (Fig. 7C–7E). Noncontact coculture signiﬁcantly reduced
the frequency of dead (7AAD1, Fig. 7F) and apoptotic cells

(7AAD-/Annexin V1, Fig. 7G) compared to HMVEC cultured alone
in EBM2. Collectively, these data indicate that factors secreted by
expanded cells prevented endothelial cell apoptosis under serumfree, growth factor-free conditions.
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DISCUSSION
The development of cell therapies to improve limb perfusion in
patients with severe PAD has been an area of intense preclinical
investigation. In previous studies, we established human ALDHhi
cells stimulate revascularization in mice with surgically-induced
limb ischemia [22, 28]. However, the low number of ALDHhi cells
in UCB limits widespread application in humans [28]. Here, we
demonstrate that UCB ALDHhi cells are readily expanded under
deﬁned, serum-free conditions without diminishing vascular

www.StemCellsTM.com

regenerative functions. After 6 days culture, we observed a >18fold increase in total cells and 7-fold expansion of clonal myeloid
progenitors. These cells retained a pro-angiogenic transcription
and protein secretory patterns that supported mature endothelial
cell survival and tube formation under growth factor restricted
conditions in vitro. Despite the loss of cells with high ALDHactivity during culture, transplantation of day 6 expanded cells
into mice with acute hindlimb ischemia accelerated the recovery
of perfusion, increased limb use, and augmented capillary density
within 7 days post-transplantation. Importantly, pro-longed
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Figure 5. Transplantation of day 6 expanded cells increased capillary density in the ischemic hind limb. (A, B): Representative photomicrographs of CD31 staining in ischemic adductor muscle sections taken 28 days after femoral artery ligation and intramuscular injection of PBS
or day 6 expanded cells. (C, D): Summary of vessel density in the ischemic or nonischemic limb at 7 or 28 days after transplantation. Mice
transplanted with fresh umbilical cord blood (UCB) ALDHhi cells or day 6 expanded cells demonstrated increased capillary density in the surgical hind limb. Data represent mean 6 SEM from 5 UCB samples. Statistical analyses were performed by ANOVA with Tukey’s multiple comparison test (*, p < .05). Abbreviations: ALDHhi, high aldehyde dehydrogenase; PBS, phosphate buffered saline.
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Figure 6. Transplantation of day 6 expanded cells increased endothelial cell proliferation in the ischemic hind limb. (A, B): Representative
photomicrographs of CD31 cell proliferation within the ischemic adductor muscle at 7 days post-transplantation. Mouse CD311EdU1 cells
(arrows) were detected in ischemic muscle of mice transplanted with day 6 expanded cells. (C): Compared to mice injected with PBS or day 9
expanded cell, mice transplanted with day 6 expanded cells showed increased endothelial cell proliferation. Data represent mean 6 SEM
from 4 umbilical cord blood (UCB) samples. Statistical analyses were performed by ANOVA with Tukey’s multiple comparison test (*, p < .05;
**, p < .01). Abbreviations: EdU, 5-ethynyl-20 -deoxyuridine; HPC, hematopoietic progenitor cell; PBS, phosphate buffered saline.

expansion out to 9 days resulted in complete loss of regenerative
function after transplantation in vitro.
Although robust total cell proliferation was observed for all 9
days in culture (38.9 6 6.0-fold), the generation of primitive
ALDHhi cells that coexpressed the progenitor cell markers CD34

and CD133 was maximal at day 6, suggesting early myeloid hematopoietic progenitor cells possessed pro-angiogenic capacity that
is lost with extended culture. Nonetheless, the overall proangiogenic stimulus contained within a single UCB sample was
enhanced by the 6 day culture protocol. As an illustration, a typical
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Figure 7. Coculture with day 6 expanded cells increased HMVEC tubule formation and survival under serum-free, growth factor reduced conditions. (A): Contact coculture with day 6 expanded cells in growth factor reduced Matrigel signiﬁcantly increased tubule formation by HMVEC at
6 and 24 hours. (B): Noncontact (transwell) coculture with day 6 expanded cells promoted HMVEC survival under growth factor-free, serumstarved conditions. (C–E): Representative ﬂow cytometry plots of apoptotic HMVEC using 7AAD and Annexin V staining. Noncontact coculture
with day 6 expanded cells decreased the frequency of dead (F): and apoptotic (G): HMVEC after 24 hours under serum and growth factor-free
conditions. Data represent mean 6 SEM from 4 umbilical cord blood samples. Statistical analyses were performed by ANOVA with Tukey’s multiple comparison test (*, p < .05; **, p < .01). Abbreviations: EBM2, endothelial basal media; EGM2, endothelial growth media; HMVEC, human
microvascular endothelial cells.

UCB sample with 4 3 105 ALDHhi cells would contain enough cells
to improve perfusion in two transplanted mice. In contrast,
expanded progeny from the same UCB sample would contain
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enough cells to improved perfusion in a minimum of 14 mice after
transplantation. Although culture of the UCB ALDHhi cell population was not required for pro-angiogenic activity after
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